Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.

These subjects are switched to an atazanavir-based regimen.

Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
Placebo: The control group will stay on their baseline regimen

Remains on Baseline HIV Regimen

These subjects are switched to an atazanavir-based regimen.
Atazanavir: The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.

Atazanavir Switch

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

The investigators will evaluate flow-mediated, brachial artery vasodilation (percentage increase in diameter in response to a 5 minute ischemic challenge) at study entry and then after 28 days, with the change between the two measurements being the primary endpoint.

Change in Flow-mediated, Endothelium-dependent Vasodilation

The investigators will evaluate plasma total antioxidant capacity at study entry and then after 28 days, with the change between the two measurements being the secondary endpoint.

Change in Plasma Total Antioxidant Capacity

Overall Study

Dr. Joshua Beckman

The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.

Atazanavir

The control group will stay on their baseline regimen

Placebo

Brigham and Women's Hospital

Atazanavir and Endothelial Function in Older HIV Patients

Joshua A. Beckman, MD

Associate Professor of Medicine

Breast Cancer

Bone Metastasis

Pain

chemoradiation

Rabin Medical Center, Beilinson Campus

Chemoradiation for Bone Metastasis

Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis

Patients were asked to score their pain on a scale of 0 (no pain) to 10 (worst possible pain) before treatment and at 1, 2, 4, 8 and 12 weeks after treatment initiation.

Consumption of analgesics was evaluated by the physician using the 5-point WHO score, as follows: level 0, no analgesics required; level 1, non-narcotic analgesics required occasionally; level 2, non-narcotic analgesics required regularly; level 3, narcotic analgesics required occasionally; level 4, narcotic analgesics required regularly

Rabin Medical Center

Sheba Medical Center

Raltegravir in combination with Tenofovir/Emtricitabine

Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine

HIV Infections

Hepatitis C

400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.

Raltegravir

Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.

Atazanavir/Ritonavir

Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital

Mater Misericordiae University Hospital

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone

Viral suppression is defined as HIV-1 RNA less than 50 copies per mL

Viral suppression is defined as HIV- RNA less than 50 copies per mL.

Effects of pharmacological intervention on corrected QT interval on electrocardiogram

Professor Colm Bergin

St. James's Hospital, Ireland

Gastric Cancer

Esophageal Cancer

Tumors

Epirubicin

Carboplatin

Capecitabine

Cross Cancer Institute

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

uridine/záhať

Atazanavir and Endothelial Function in Older HIV Patients

Chemoradiation for Bone Metastasis

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Nejúplnější databáze léčivých bylin podložená vědou